Clinical Trials

9 results for Kidney/Renal Cancer

A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

  • Condition: Renal Cell Carcinoma
  • Intervention: Device: CyberKnife
  • Study ID: NCT01890590
View Trial

177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.

  • Condition: Thyroid Cancer, Medullary
  • Intervention: Drug: 177Lu-PP-F11N
  • Study ID: NCT02088645
View Trial

Kidney Cancer DNA Registry

  • Condition: Renal Cancer
  • Intervention: Other: salvia for germline DNA, Behavioral: the Kidney Cancer Questionnaire, Behavioral: Family History Questionnaire (when applicable)
  • Study ID: NCT02087852
View Trial

Development and Evaluation of High Risk Group Prediction Model in T1 Stage Renal Cell Cancer Using Molecular Biomarkers

  • Condition: Clear Renal Cell Cancer (< 7cm Size)
  • Intervention: Procedure: Partial or radical nephrectomy
  • Study ID: NCT03694912
View Trial

Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors

  • Condition: Renal Tumor
  • Intervention: Radiation: Stereotactic Ablative Radiotherapy
  • Study ID: NCT03747133
View Trial

Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies

  • Condition: Clear Cell Renal Cell Carcinoma, Locally Advance Pancreatic Ductal Adenocarcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Pancreatic Ductal Ad
  • Intervention: Drug: ATR Kinase Inhibitor AZD6738, Drug: Olaparib
  • Study ID: NCT03682289
View Trial

An International Investigator-led Phase III Multi Arm Multi Stage Multi-centre Randomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse

  • Condition: Renal Cell Carcinoma
  • Intervention: Drug: Durvalumab, Drug: Tremelimumab
  • Study ID: NCT03288532
View Trial

Monitoring of Treatment Related Toxicities From Oral Targeted Agents and Immunotherapy Among Patients With Advanced Renal Cell Carcinoma (RCC) Using Carevive Software, a Single-Arm Phase II Feasibility Study

  • Condition: Advanced Renal Cell Carcinoma
  • Intervention: Other: Carevive software
  • Study ID: NCT03229083
View Trial

Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

  • Condition: Renal Cell Carcinoma
  • Intervention: Drug: Nivolumab, Drug: Axitinib
  • Study ID: NCT03172754
View Trial